Treatment Effect of Conversion Therapy and Its Correlation with VEGF Expression in Unresectable Rectal Cancer with Liver Metastasis

Overview

Journal Oncol Lett

Specialty Oncology

Date 2018 Jul 3

PMID 29963141

Citations 3

Authors

Ge Hou

Rui Song

Jun Yang

Yanling Zhang

Chenhu Xiao

Cheng Wang

Jinjin Yuan

Ting Chai

Zongwen Liu

Affiliations

Soon will be listed here.

Abstract

To investigate the therapeutic effect of conversion therapy and its correlation with vascular endothelial growth factor (VEGF) expression in unresectable rectal cancer with liver metastasis. A total of 116 cases of unresectable rectal cancer patients with liver metastasis were randomly divided into control and observation group, 58 cases in each group, all of these patients were treated by conversion therapy, patients in control were treated by FOLFOXIRI treatment program, and in observation group were treated by FOLFOXIRI program treatment and bevacizumab. Efficacy and adverse reactions were compared between the two groups, the levels of VEGF in portal vein and the expression of VEGF in cancer tissue were compared, after 5 years of follow-up, the prognosis of the two groups were observed. Objective efficiency and conversion rate of observation was significantly higher than the control group, survival rate of postoperative observation was significantly higher than that of control group (P>0.05). There was no significant difference in adverse reactions between the two groups (P>0.05). The positive rate of VEGF in portal vein blood and the expression of VEGF in the observation was significantly lower than that in the control group (P<0.05). The 5-year survival rate of VEGF high expression was significantly lower than that of VEGF low expression group (P<0.05). FOLFOXIRI combined with bevacizumab in patients with unresectable hepatic metastasis of rectal cancer can provide higher conversion rate and hepatectomy opportunities, and reduce VEGF expression in patients with unresectable rectal cancer, which is closely related to VEGF expression, therefore it is beneficial to better local control and to improve long-term survival.

Citing Articles

Efficacy and Safety of Systemic Treatments Among Colorectal Cancer Patients: A Network Meta-Analysis of Randomized Controlled Trials.

Hoang T, Sohn D, Kim B, Cha Y, Kim J Front Oncol. 2022; 11:756214.

PMID: 35223449 PMC: 8864322. DOI: 10.3389/fonc.2021.756214.

Hoang T, Kim J Cancers (Basel). 2020; 12(9).

PMID: 32961943 PMC: 7565292. DOI: 10.3390/cancers12092663.

Expression of vascular endothelial growth factor as a predictor of complete response for preoperative chemoradiotherapy in rectal cancer.

Yu J, Lee S, Jeung T, Chang H Medicine (Baltimore). 2019; 98(26):e16190.

PMID: 31261557 PMC: 6617461. DOI: 10.1097/MD.0000000000016190.

References

Van Cutsem E, Lenz H, Kohne C, Heinemann V, Tejpar S, Melezinek I . Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015; 33(7):692-700. DOI: 10.1200/JCO.2014.59.4812. View

Glimelius B, Ristamaki R, Kjaer M, Pfeiffer P, Skovsgaard T, Tveit K . Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol. 2002; 13(12):1868-73. DOI: 10.1093/annonc/mdf324. View

Dunet V, Halkic N, Prior J, Anaye A, Meuli R, Sempoux C . Detection and Viability of Colorectal Liver Metastases After Neoadjuvant Chemotherapy: A Multiparametric PET/CT-MRI Study. Clin Nucl Med. 2017; 42(4):258-263. DOI: 10.1097/RLU.0000000000001538. View

Brenner H, Kloor M, Pox C . Colorectal cancer. Lancet. 2013; 383(9927):1490-1502. DOI: 10.1016/S0140-6736(13)61649-9. View

Venderbosch S, Nagtegaal I, Maughan T, Smith C, Cheadle J, Fisher D . Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014; 20(20):5322-30. PMC: 4201568. DOI: 10.1158/1078-0432.CCR-14-0332. View

Wagner M, Ronot M, Doblas S, Giraudeau C, Van Beers B, Belghiti J . Assessment of the residual tumour of colorectal liver metastases after chemotherapy: diffusion-weighted MR magnetic resonance imaging in the peripheral and entire tumour. Eur Radiol. 2015; 26(1):206-15. DOI: 10.1007/s00330-015-3800-6. View

Heinemann V, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S . FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(10):1065-75. DOI: 10.1016/S1470-2045(14)70330-4. View

Sotirchos V, Petrovic L, Gonen M, Klimstra D, Do R, Petre E . Colorectal Cancer Liver Metastases: Biopsy of the Ablation Zone and Margins Can Be Used to Predict Oncologic Outcome. Radiology. 2016; 280(3):949-59. PMC: 5006720. DOI: 10.1148/radiol.2016151005. View

Jagadish N, Parashar D, Gupta N, Agarwal S, Sharma A, Fatima R . A novel cancer testis antigen target A-kinase anchor protein (AKAP4) for the early diagnosis and immunotherapy of colon cancer. Oncoimmunology. 2016; 5(2):e1078965. PMC: 4801464. DOI: 10.1080/2162402X.2015.1078965. View

10.

Ciamporcero E, Miles K, Adelaiye R, Ramakrishnan S, Shen L, Ku S . Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther. 2014; 14(1):101-10. PMC: 4297225. DOI: 10.1158/1535-7163.MCT-14-0094. View

11.

Page A, Weiss M, Pawlik T . Surgical management of noncolorectal cancer liver metastases. Cancer. 2014; 120(20):3111-21. DOI: 10.1002/cncr.28743. View

12.

Kahi C, Boland C, Dominitz J, Giardiello F, Johnson D, Kaltenbach T . Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer. Gastrointest Endosc. 2016; 83(3):489-98.e10. DOI: 10.1016/j.gie.2016.01.020. View

13.

Jannuzzi A, Ozhan G, Yanar H, Alpertunga B . VEGF gene polymorphisms and susceptibility to colorectal cancer. Genet Test Mol Biomarkers. 2015; 19(3):133-7. DOI: 10.1089/gtmb.2014.0259. View

14.

Bregendahl S, Emmertsen K, Fassov J, Krogh K, Zhao J, Gregersen H . Neorectal hyposensitivity after neoadjuvant therapy for rectal cancer. Radiother Oncol. 2013; 108(2):331-6. DOI: 10.1016/j.radonc.2013.07.004. View

15.

Corley D, Jensen C, Marks A, Zhao W, Lee J, Doubeni C . Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014; 370(14):1298-306. PMC: 4036494. DOI: 10.1056/NEJMoa1309086. View

16.

Truant S, Sequier C, Leteurtre E, Boleslawski E, Elamrani M, Huet G . Tumour biology of colorectal liver metastasis is a more important factor in survival than surgical margin clearance in the era of modern chemotherapy regimens. HPB (Oxford). 2014; 17(2):176-84. PMC: 4299392. DOI: 10.1111/hpb.12316. View

17.

Li J, Hao D, Wang L, Wang H, Wang Y, Zhao Z . Epigenetic targeting drugs potentiate chemotherapeutic effects in solid tumor therapy. Sci Rep. 2017; 7(1):4035. PMC: 5481380. DOI: 10.1038/s41598-017-04406-0. View

18.

Hamnvik O, Choueiri T, Turchin A, McKay R, Goyal L, Davis M . Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2014; 121(2):311-9. PMC: 4293233. DOI: 10.1002/cncr.28972. View